Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer

13 Jul 2022

Abstract excerpt

Abstract The efficacy of immune checkpoint blockade (ICB) varies greatly among metastatic non-small cell lung cancer (NSCLC) patients. Loss of heterozygosity at the HLA-I locus (HLA-LOH) has been identified as an important immune escape mechanism. However, despite HLA-I disruptions in their tumor, many patients have durable ICB responses. Here we seek to identify HLA-I-independent features associated with ICB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35831288
DOI: 10.1038/s41467-022-31769-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancerPMID 35831288Read ↗

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.Semantic proximity Read ↗

Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapySemantic proximity Read ↗

Genetic immune escape landscape in primary and metastatic cancerSemantic proximity Read ↗

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.Semantic proximity Read ↗

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Genetic immune escape landscape in primary and metastatic cancerSemantic proximity Read ↗

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read ↗

Molecular architecture of the tumor microenvironment caused by <i>BRCA1</i> and <i>BRCA2</i> somatic mutations in lung adenocarcinomaSemantic proximity Read ↗

Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.Semantic proximity Read ↗

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.Semantic proximity Read ↗

Genetic immune escape landscape in primary and metastatic cancer.Semantic proximity Read ↗

Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.